To investigate the percutaneous coronary intervention (PCI), perioperative atorvastatin strengthen the treatment of restenosis of coronary heart disease ( CHD) patients. Methods Select the period in our hospital from January 2008 to November 2011 accepted 116 cases of elective PCI patients with CHD as the research object. Were randomly divided into experimental and control groups, each group of 58 cases. Two groups of patients admitted to hospital to receive conventional treatment control group on the basis of conventional therapy plus statin 20mg / d, the experimental group and atorvastatin with atorvastatin statin 80mg/d, in both groups at 2 weeks of treatment underwent PCI surgery was still taking 12 months. Both groups were followed for 12 months, two groups were compared during follow-up in-stent restenosis and adverse cardiovascular event occurrence. Results Follow-up period, the experimental group in-stent restenosis and acute myocardial infarction, revascularization, cardiac death incidence was significantly lower than the control group (P < 0. 01 ). The two groups of patients with drug-common adverse events compared to the situation, the difference was not statistically significant ( P > 0.05). Conclusion The PCI perioperative strengthen dose (80mg/d), atorvastatin therapy con effectively reduce the CHD patients in-stent restenosis rate andcardiovascular adverse event rates, and the use of process safety.%目的 探讨经皮冠脉介入治疗(PCI)围术期阿托伐他汀强化治疗对冠心病(CHD)患者术后再狭窄的影响.方法 选择2008年1月～2011年11月期间于本院住院接受择期PCI术的CHD患者116例为研究对象.随机分为试验组和对照组,每组58例.两组患者入院后均接受常规治疗,对照组在常规治疗基础上加用阿托伐他汀20mg/d,试验组加用阿托伐他汀80 mg/d,两组均于治疗2周后行PCI术,术后继续服用12个月.两组均随防12个月,比较两组患者在随访期间支架内再狭窄及不良心血管事件的发生情况.结果 随访期间,试验组支架内再狭窄率及急性心肌梗死、血管重建术、心脏性死亡发生率均显著低于对照组(P＜0.01).两组患者药物常见的不良反应发生情况比较,差异无统计学意义(P均＞0.05).结论 PCI围术期应用强化剂量(80mg/d)阿托伐他汀治疗,可有效降低CHD患者术后支架内再狭窄率和心血管不良事件发生率,且使用过程安全.
展开▼
